| Basics |
Dynavax Technologies Corporation
Dynavax Technologies Corp is a clinical-stage biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor ("TLR") stimulation.
|
| IPO Date: |
February 19, 2004 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$1.28B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.22 | 3.03%
|
| Avg Daily Range (30 D): |
$0.27 | 2.18%
|
| Avg Daily Range (90 D): |
$0.19 | 1.49%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.36M |
| Avg Daily Volume (30 D): |
2.06M |
| Avg Daily Volume (90 D): |
1.77M |
| Trade Size |
| Avg Trade Size (Sh.): |
189 |
| Avg Trade Size (Sh.) (30 D): |
92 |
| Avg Trade Size (Sh.) (90 D): |
95 |
| Institutional Trades |
| Total Inst.Trades: |
4,334 |
| Avg Inst. Trade: |
$2.38M |
| Avg Inst. Trade (30 D): |
$2.64M |
| Avg Inst. Trade (90 D): |
$3.04M |
| Avg Inst. Trade Volume: |
.19M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.96M |
| Avg Closing Trade (30 D): |
$4.53M |
| Avg Closing Trade (90 D): |
$4.05M |
| Avg Closing Volume: |
248.09K |
|
|
|
|
| Financials |
| |
TTM |
Q4 2024 |
FY 2024 |
|
Basic EPS
|
$.21
|
$.06
|
$.21
|
|
Diluted EPS
|
$.2
|
$.05
|
$.2
|
|
Revenue
|
$ 277.25M
|
$ 72.03M
|
$ 277.25M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ 27.31M
|
$ 7.05M
|
$ 27.31M
|
|
Operating Income / Loss
|
$ -4.12M
|
$ -1.63M
|
$ -4.12M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -54.4M
|
$ -23.46M
|
$ -54.4M
|
|
PE Ratio
|
57.30
|
|
|
| Splits |
| Nov 10, 2014:
10:1
|
|
